Phase1 may demonstrate target engagement, page-28

I agree pivalde, but Prana seem to be avoiding anything specific about it so far. In one section of the 2017 Annual Report they stated that a non neuro use had been found for PBT2. Then the patent file "Method of Treating Immunoglobulin Light Chain Amyloidosis" mentioned "use of a known compound for the treatment of cardiac toxicity associated with light chain amyloidosis". I suppose we are supposed to guess that is PBT2, but at the start of the report in the chairmans letter we have "Following the Company’s review of its development programs, further development of PBT2 will remain on hold."
Have you seen any indication that Prana have any work being done on PBT2 and light chain conditions?